




Institute of Infection and Immunity

Annual Report 2001-2002





CIHR – Institute of Infection and Immunity
Siebens-Drake Research Institute, Suite 214
The University of Western Ontario
1400 Western Road
London, ON N6G 2V4
Fax (519) 661-4226
www.cihr-irsc.gc.ca

© Her Majesty the Queen in Right of Canada (2002)

Cat. No.: MR1-12/2002

ISBN 0-662-32538-9





Institute of Infection and Immunity

Annual Report 2001-2002





Table of Contents

	Message from the Scientific Director	2
	Institute Staff	3
	Profile of the Institute	4
	Outstanding Research	6
	Excellent Researchers and a Robust Research Environment	9
	Partnerships and Public Engagement	15
	Translation and Use of Knowledge	19
	Organizational Excellence	21
	Financial Statements	25
	Appendices	27



Message from the Scientific Director

The creation of the CIHR Institute of Infection and Immunity has provided a unique opportunity and challenge in its mandate of helping to coordinate a national health research agenda for Canada. During its first year of operation, the Institute established a base at the University of Western Ontario, and moved quickly to mobilize the research community, non-profit agencies, federal government departments and the private sector towards developing a national vision for health research in the areas of infectious diseases and immunology. As a consequence, the Institute is actively developing programs and partnerships with stakeholders from diverse backgrounds to create a new vision of health research that will have a significant impact on the care of patients and lead to a reduction in the burden of illness.

In the past year, the Institute has participated in and supported meetings, workshops and conferences devoted to the development of a robust infection and immunity research agenda in Canada, and has launched several strategic research initiatives. These include the CIHR Training Program Grants, the New Emerging Teams program and the Health Research Programs of Excellence. In addition, the Institute has responded to emerging challenges such as bioterrorism, the microbiological safety of food and water, tissue graft rejection and global challenges in infectious diseases, including HIV/AIDS and hepatitis C, by sponsoring and participating in meetings and consultations.

The Institute is not a funding agency, but a champion and partner in supporting excellent research that will have short, medium and long-term returns on the investment that Canadians have made in health research through CIHR. Our goal is to manage this investment to improve the health of Canadians and maintain accountability throughout the process. The current research funding from CIHR in the areas of infection and immunity is approximately \$75 million per year. Many other provincial and federal government agencies and departments, as well as non-profit organizations, also provide substantial research funding in this area.

The Institute is guided by a dedicated and diverse group of talented individuals that forms the Institute Advisory Board, chaired by Dr. Lorne Babiuk of the University of Saskatchewan. The advisory board contributed time and energy to the formulation of the Institute Strategic Plan and guided its implementation in a timely fashion. Over the last year, the Institute has recruited Bruce Moor as Assistant Director and Carol Richardson as Administrative Officer here in London. The Institute is fortunate to have Dr. Judith Bray, who was instrumental in the early evolution of the Institute, as the Institute Liaison Officer based at CIHR in Ottawa. I thank Dr. Grace Parraga for providing help in drafting the strategic plan, and Patrick Haag at CIHR in Ottawa for providing valuable help in formalizing the graphics and communications plans of the Institute.

I would also like to thank all those who attended various public forums and consultation meetings to provide input into our strategic planning process. This report highlights the exciting work that has gone on in the past year to establish our virtual Institute. I welcome your continuing input into this process because it is essential for our future success. Finally, I would like to thank the Governing Council of CIHR and CIHR President Dr. Alan Bernstein, for their support and for the opportunity to be part of this exciting new national endeavour.

A handwritten signature in black ink that reads "Bhagirath Singh". The signature is written in a cursive style.

Bhagirath Singh Ph.D.

Scientific Director, CIHR Institute of Infection and Immunity
Scientist, Robarts Research Institute
Professor, Department of Microbiology & Immunology,
University of Western Ontario

Institute Staff



Dr. Bhagirath Singh

Scientific Director
bsingh@uwo.ca
(519) 661-3228



Dr. Judith Bray

Assistant Director, Special Projects
jbray@cihr.gc.ca
(613) 954-7223



Bruce Moor

Assistant Director
bmoor@uwo.ca
(519) 661-3228



Patrick Haag

Project and Communications Officer
phaag@cihr.gc.ca
(613) 946-1270



Carol Richardson

Administrative Officer
carol.richardson@fmd.uwo.ca
(519) 661-3228

Profile of the Institute

The Institute of Infection and Immunity (III) is one of 13 Institutes of the Canadian Institutes of Health Research (CIHR). All 13 Institutes have been created to promote and build upon Canada's foundation of health research excellence with support from the lay community and the volunteer, professional, and private sectors. The Institutes are engaging the research community and encouraging interdisciplinary, integrative health research. The Institutes will work together to forge a health research agenda across disciplines, sectors, and regions; this agenda will embrace scientific opportunity and reflect the emerging health needs of Canadians, the evolution of the health care system and the information needs of health policy decision-makers. Each Institute is expected to facilitate partnerships and accelerate the translation of new knowledge into benefits for Canadians.

The Institute of Infection and Immunity seeks to achieve national and global leadership through supporting health and public policy research on the control of infectious diseases, and to harness healthy immune responses to protect against and mitigate a wide range of health challenges. The Institute is built on a strong foundation of Canadian research funded through the

investigator-initiated CIHR programs, which it will leverage in the creation of strategic initiatives and targeted development activities. Our goal is to create a robust research capacity that is well equipped to address ongoing and emerging challenges in infection and immunity research.

The Institute is based at the University of Western Ontario, the home institution of its Scientific Director, Dr. Bhagirath Singh, whose areas of research expertise include molecular immunology, antigen presentation, microbial regulation of autoimmunity and diabetes.

The Institute is supported by an advisory board of 15 individuals with exceptional qualifications and demonstrated leadership abilities in a broad range of areas within the Institute's mandate (see Appendix 1).

These areas include research expertise in:

- viral and bacterial pathogenesis
- vaccine development and delivery
- antimicrobial resistance
- HIV/AIDS
- lymphocyte functions
- bioethics
- transplantation biology
- clinical transplantation
- gene therapy



- population health aspects of infectious disease
- autoimmunity
- host resistance
- immunoregulation
- epidemiology
- health services research
- lay expertise in communications, fundraising and volunteer organizations

Geographically, the board members are based from coast to coast in Canada, with two members based in the United States. Collectively, the advisory board is uniquely equipped to assist in shaping Institute research programs.

The Institute of Infection and Immunity Institute Advisory Board. From left, Lorne Babiuk, IAB Chair; Jack Gauldie; Bhagirath Singh, III Scientific Director; Helaine Shiff; William E. Paul; Michel Bergeron; Brett Finlay; Danielle Malo; Frank Plummer; Chris Bleackley; Kevin Glasgow; Noni MacDonald and Abdallah Daar (Absent: Philip Halloran, Steffanie Strathdee, and Robyn Tamblin).



Operationally, the Institute is supported by administrative teams based in both Ottawa at the CIHR secretariat and at the University of Western Ontario. For the period of this report, the team included an Institute Liaison Officer, an Assistant Director, an Administrative Officer, and a Project Officer. Implementation of Institute programs is effected by this team, and is extensively supported by CIHR staff in Ottawa. This structure, once fully operational, will engender a targeted and responsive outreach capacity which is unprecedented among Canadian granting councils.



Outstanding Research

Foundation of the Institute

Infectious agents and immune system issues pose some of the most serious threats to our quality of life. The Walkerton tragedy, the increasing number of organisms resistant to antibiotics, and the ongoing expansion of the HIV/AIDS epidemic all demonstrate the need for research that illuminates the biology of infectious agents and immune-mediated disease. Infectious diseases affect all sectors of society, and, on a global basis, remain the leading cause of human death. It is critically important that knowledge derived from basic research on pathogens and the immune system is translated into effective clinical treatments and public health policies that improve the health of Canadians.

Canada is fortunate to have a foundation of excellence in infection and immunity research, and a strong history of collaboration among researchers in the area. Major discoveries in infectious diseases research such as the anti-HIV drug lamivudine, the creation of an effective meningitis vaccine, and the discovery of the T-cell receptor were made by Canadian scientists. Collaboration among infection and immunity scientists has resulted in two Networks of Centres of

Excellence — the Canadian Bacterial Diseases Network (CBDN) and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) — as well as the HIV Clinical Trials Network, and a number of research centres and private sector enterprises.

In 2001, 14 per cent of the currently supported CIHR principal investigators and co-investigators, or 1,022 researchers, were involved in some aspect of infection or immunity research. These researchers formed the foundation that was the driving force for the creation of the Institute of Infection and Immunity, and will continue to provide the intellectual reservoir from which advancements in Canadian infectious disease and immune research will spring. They will provide mentors to train the next generation of researchers, and expertise to address emerging research problems. A major challenge facing the Institute is to identify areas where additional capacity and networks can be built to enhance Canadian scientific capabilities. To focus the initial work of the Institute, an important activity of the first year was drafting the first strategic plan.





Strategic Planning

Beginning in March 2001 with the first meeting of the Institute Advisory Board (IAB), the Institute embarked on a strategic planning process to set its direction and identify its initial strategic research priorities. At this meeting, the vision, mission and a number of guiding principles were defined, and a process for the development of a strategic plan was set in motion. This process incorporated the extensive input received from Canadian stakeholders preceding the establishment of the Institute, and extended this input with interviews and surveys of researchers, key stakeholders, societies, professional organizations, health charities and the lay

community. A significant component of this consultation process was the direct interaction of the Scientific Director with researchers at 12 university and six professional society venues across Canada (see Appendix 2). The results of these consultations were iteratively refined by the Advisory Board, and the Institute's draft strategic plan was completed in March 2002. This plan identifies the following 10 priority research themes on which to focus the development of the Institute's strategic activities for its first few years:

- Research Training and Career Development
- Microbial Safety of Food and Water
- Antimicrobial Resistance in Pathogens

Researchers and politicians attending a symposium sponsored by the Institute of Infection and Immunity. From left, Dr. Miguel Valvano, Department of Microbiology and Immunology, the University of Western Ontario; Vice President (Research) Dr. Nils Petersen, the University of Western Ontario; Institute Advisory Board Chair Dr. Lorne Babiuk; Dr. C. Yong Kang, Department of Biology and Department of Microbiology and Immunology, the University of Western Ontario; MP Sue Barnes; Dr. R.G.E. Murray, Professor Emeritus of Microbiology and Immunology, the University of Western Ontario; and Institute Advisory Board member Dr. Danielle Malo.



- The HIV/AIDS Health Challenge
- Hepatitis C/Blood-borne Infections
- Innovative Vaccine Development and Delivery
- Asthma, Allergy, Host Resistance and Innate Immunity
- Autoimmune Diseases, with a Focus on Type 1 Diabetes
- Stem Cell Biology, Transplantation and Regenerative Medicine
- Response to Emerging Challenges

The impact of these priorities on the programs of the Institute is illustrated in subsequent sections of this report. Requests for applications (RFA) were launched in six of these priority areas within the last year, and significant developmental work was carried out in three other priority areas. This and ongoing work will result in RFA to be launched in the 2002/2003 year and beyond.

The selection of initial strategic priorities does not end the process of consultation. Key to the ultimate success of the Institute of Infection and Immunity will be an ongoing dialogue with researchers and stakeholders relating to the Institute mandate. Going forward, the Institute will support workshops, conferences and consensus meetings which provide information and direction for the continued development of Institute programs and networks. It is vital that many of these opportunities be initiated by “grass roots” constituents, especially in emerging areas of scientific development. Over the last 15 months, the Institute has committed financial support to nine such activities; several of these were partnerships that brought together three or more of the CIHR Institutes around a theme of mutual interest. Such meetings have already been crucial for the formation and implementation of new interdisciplinary teams and networks that CIHR is seeking to stimulate.



Excellent Researchers and a Robust Research Environment

The Canadian Institutes of Health Research and its predecessor the Medical Research Council of Canada have made substantial investments in the support of research relating to the Institute of Infection and Immunity. Of the 6,831 grants and personnel awards receiving CIHR support during the period of this report, 875 are within the Institute's mandate. In dollar terms, this represents more than \$69.5 million, approximately 14 per cent of the budget of \$494.5 million for these awards. Cataloguing the many personnel awards supporting infection and immunity researchers is difficult, but at least 40 of the 532 Canada Research Chairs to date perform research in Institute-related areas, and three of six CIHR Distinguished Scientist awards presented in 2001 went to researchers with strong programmatic connections to the Institute.

With this research capacity as a base, the Institute has used its priorities to focus the first strategic programs. With an initial budget of \$2.4 million annually, the range and size of these programs was necessarily constrained, and addressed only a small fraction of the possibilities represented in the CIHR investigator-initiated programs. The strategic budget will increase in future years, and the Institute will strive to leverage this budget with additional support from its partners. Nevertheless, the programs described below represent significant extensions to the range of research supported by CIHR.

CIHR Training Program

Strategic Priority: Research Training and Career Development

By the year 2010, Canada will be facing an estimated shortfall of 100,000 researchers and scientists. The Canadian Institutes of Health Research believes in investing in the training of new health care researchers and in the ongoing support and development of already established researchers. Toward these ends, the Institutes launched specific funding initiatives aimed at building research capacity in strategic areas through the support of training programs. This new model for the enhancement of Canadian research capacity was enthusiastically received by the research community and 51 training programs were funded in the spring of 2002. Eleven of these programs (see Table 1) fall within the mandate of the Institute of Infection and Immunity and its partners, and the Institute is the lead CIHR Institute for seven of these. These seven programs will support research in areas relating to health challenges in transplantation, allergy and asthma, antimicrobial resistance and infectious diseases.




Table 1
Strategic Training Initiative in Health Research Grants in the Areas of
Infection and Immunity

December 2001

Principal Investigator	Affiliation	Program Title	Sponsors * = Lead	Total award
CHUNG, Stephen W	University of British Columbia	Transplantation	Heart & Stroke Foundation of Canada, Michael Smith Foundation for Health Research, ICRH, IHSPR, III* and INMD	\$ 1,800,000
DOSMAN, James A	University of Saskatchewan	Public health and the agricultural rural ecosystem	ICR, ICRH, III and IPPH*	\$ 1,703,952
ELLEN, Richard P	University of Toronto	Cell signaling in mucosal inflammation & pain	Michael Smith Foundation for Health Research, The Arthritis Society*, ICRH, IHSPR, III, IMHA*, INMD and CIHR	\$ 1,797,256
HAYGLASS, Kent T	University of Manitoba	Allergy and asthma: From molecular regulation to population health	ICRH*, IHDCYH*, IHSPR, III* and IPPH	\$ 1,800,000
KUBES, Paul	University of Calgary	Health research: A transdisciplinary training program in diseases of immunopathogenesis and inflammation	Alberta Heritage Foundation for Medical Research, ICRH, III*, IMHA, INMD and CIHR	\$ 1,578,404
LEVY, Gary A	University of Toronto	Regenerative medicine	ICRH, III* and INMD*	\$ 1,784,368
PLUMMER, Francis A	University of Manitoba	International centre for infectious diseases training program	IAPH, III*, IPPH and CIHR	\$ 1,800,000
REITHMEIER, Reinhart A	Hospital for Sick Children (Toronto)	Structural biology of membrane proteins linked to disease	ICR, ICRH, IG*, III, INMD and INMHA	\$ 1,800,000
ROY, Paul H	Centre hospitalier de l'Université Laval (Québec)	Résistance aux agents antimicrobiens	Fonds de la recherche en santé du Québec and III*	\$ 1,638,000
SCHURR, Erwin A	Hôpital général de Montréal	Infectious diseases and autoimmunity	Fonds de la recherche en santé du Québec, IGH, III*, IMHA, IPPH and CIHR	\$ 1,800,000
TESCHKE, Kay	University of British Columbia	To bridge public health, engineering and policy research	Michael Smith Foundation for Health Research*, III, IPPH* and CIHR	\$ 1,800,000

From left to right, Dr. I. George Fantus, Dr. David Hill and Dr. Allan Becker are the principal investigators for three successful applications in the December 2001 New Emerging Teams competition.



Clinician Scientists

Strategic Priority: Research Training and Career Development

Integral to the CIHR vision is a problem-based, multi-disciplinary approach to important research questions and health challenges. This multidisciplinary approach brings scientists together who have diverse academic backgrounds, research expertise and interests. In a health research climate, the clinician scientist brings to the research arena the accumulated knowledge of at least two disciplines and thus offers particularly rich insight into the mechanisms by which research knowledge can be translated and applied to clinical practice and vice versa.

CIHR has identified a decline in Canada's clinician scientist capacity and is drafting a series of recommendations for the development of policies and support programs to cultivate clinician scientists working across the country. In concert with this initiative, the Institute of Infection and Immunity, with its partners Health Canada's Office of the Chief Scientist and the National Microbiology Laboratory, has signed a Memorandum of Understanding that will co-fund up to three clinician scientists. Not only will this partnership promote collaboration between CIHR and Health Canada, but it will also increase research capacity in areas of infectious diseases which may include virology, bacteriology, HIV, tuberculosis, sexually transmitted diseases, blood-borne pathogens,

prion diseases, zoonotic diseases or enterics. The research will take place at the world-class facilities of the National Microbiology Laboratory at the Canadian Science Centre for Human and Animal Health in Winnipeg, Manitoba, and associated research institutions.

This agreement was signed in late November, 2001; interested applicants will apply to the September 15, 2002 competition for Clinician Scientists, phase 1.


New Emerging Teams

Strategic Priorities: Autoimmune Diseases, with a Focus on Type 1 Diabetes; Asthma, Allergy, Host Resistance and Innate Immunity

The New Emerging Team (NET) program is a new CIHR tool for supporting the growth of small teams or the creation of new teams of independent investigators. The projects undertaken by these teams are collaborative, multidisciplinary and innovative.

Type 1 Diabetes and its Complications

Type 1, or juvenile, diabetes is a disease that strikes suddenly, making the patient insulin-dependent for life. It can cause serious complications including kidney failure, blindness, nerve damage, amputations, heart attack and stroke. The creation of a NET program specifically targeting this disease offers hope for the millions affected by it.





The Juvenile Diabetes Research Foundation (JDRF) International is the world's leading non-profit, non-governmental funder of diabetes research. The Institute of Infection and Immunity, with the CIHR Institute of Nutrition, Metabolism and Diabetes and the Institute of Human Development, Child and Youth Health, signed a Memorandum of Understanding with JDRF to fund NET applications in Type 1 diabetes. Two five-year programs have been funded, with a total award of \$2.4 million (see Table 2).

Asthma: Predisposing Factors, Health Outcomes and Prevention

The etiology of asthma is complex and involves the interactions of predisposing genes, the immune response, allergens and environmental factors. Treatment of asthma is a significant

and increasing challenge for the Canadian health care system. The goal of this NET program is to advance the understanding of the genetic, immunological and environmental interactions that cause asthma, and to determine ways of preventing asthma in adults and children.

The CIHR Institutes of Infection and Immunity, Circulatory and Respiratory Health, and Human Development, Child and Youth Health called for applications which demonstrated a good integration of research effort towards addressing the underlying mechanisms that cause asthma, predisposing risk factors, treatment and prevention strategies, and impacts on health services and systems. One five-year program received funding with a total award of \$1.2 million.

**Table 2
New Emerging Teams**

December 2001

Principal Investigator	Affiliation	Title	Sponsors	Total award
FANTUS, Ivan	Samuel Lunenfeld Research Institute (Toronto)	Glucose toxicity: Prevention of diabetes complications and preservation of pancreatic beta cell function	JDRF, III, INMD, IHDCYH	\$ 1,163,750
HILL, David	Lawson Health Research Institute/ University of Western Ontario	Pancreatic islet generation from human stem cells	JDRF, III, INMD, IHDCYH	\$ 1,232,630
BECKER, Allan	University of Manitoba	Origins of asthma in childhood: The role of gene: environment interactions	III, ICRH, IHDCYH	\$ 1,233,000





Dr. Lorne Babiuk and Dr. David Kelvin are the principal investigators for two successful applications in the November 2001 Health Research Programs of Excellence.

Health Research Programs of Excellence

Strategic Priorities: Innovative Vaccine Development and Delivery; Stem Cell Biology, Transplantation and Regenerative Medicine

Health Research Programs of Excellence are transdisciplinary research programs representing at least two of the four themes of health research, with an emphasis on research translation between the themes, and focused on an important health problem. Applicants to this strategic initiative were required to demonstrate ongoing, active and substantive working relationships among the team's researchers, to emphasize the discovery of new knowledge and to describe strategies for translation of research findings into improvements in the health of Canadians.

The Institute targeted two of its priority areas in this round of RFA – *Innovation in Organ and Cell Transplantation and Innovative Vaccine Development and Delivery to Prevent Infectious Diseases*. The former sought to address the current inadequate supply of donated organs and to improve, through transplantation, the quality of life for those with end-stage organ failure. The latter focused on vaccine development and delivery platforms, with emphasis on vaccines for infectious diseases of particular importance to human health, such as hepatitis C and HIV/AIDS. Two five-year programs, totalling \$3.8 million, have been funded in this initiative (see Table 3).

Table 3
Health Research Programs of Excellence

November 2001

Principal Investigator	Affiliation	Project Title	Total Award
BABIUK, Lorne A	University of Saskatchewan	<u>Vaccinology</u> Innovative vaccine development and delivery to induce mucosal immunity	\$ 1,886,000
KELVIN, David J	University Health Network-Toronto	<u>Transnet</u> Molecular modeling of alloantigen independent and alloantigen dependent transplantation injury	\$ 1,887,400



HIV/AIDS

Strategic Priority: The HIV/AIDS Health Challenge


The first cases of AIDS were reported on this continent in 1981; in the 20 years since, the disease has become an epidemic of global proportions. Although health care, volunteer and research communities continue to support those with the disease, focus on prevention and search for a cure, the disease continues to spread. In Canada, transmission rates have generally stabilized, but continue to rise in the aboriginal community. On March 1, 2002, the Institute of Aboriginal People's Health in partnership with the Institute of Infection and Immunity launched a strategic research initiative to not only address the epidemic in the aboriginal population but also to involve aboriginal communities and organizations in the development of the initiative.

CIHR Cross-Institute Strategic Initiatives

Institute strategic priorities are also represented in CIHR's selection of research areas to receive funding from a centralized strategic funding pool. The Institute of

Infection and Immunity welcomes these opportunities to expand and diversify its partnerships and maintain its goals of supporting and engaging the infection and immunity research communities. These research areas cut across several themes and thus are important to the health of Canadians on a larger scale. Proposed by the CIHR Research Priority and Planning Committee in January 2002, the initiatives are:

- Genetics and Environmental Interactions in Determining Health and Disease
- Regenerative Medicine
- Rural and Northern Health
- Reducing Health Disparities and Promoting the Health of Vulnerable Populations
- Clinician Scientists: Recruitment and Retention
- Environment Influences on Health
- Global Health Research
- Tobacco Abuse and Nicotine Addiction
- Strategic Injury Research Initiatives



Partnerships and Public Engagement

Biological Terrorism:

Canadian Research Agenda (January 18-20, 2002)

The anthrax attacks following the events of September 11, 2001 in the U.S. highlighted the magnitude of the threat posed by bio-terrorists. Institute of Infection and Immunity researcher and advisory board Chair Dr. Lorne Babiuk has spoken publicly of the ease and economy with which biological weapons can be made, making them what he calls “the poor man’s nuclear weapons.” The Institute of Infection and Immunity, in partnership with Health Canada, the Institute of Population and Public Health, the Institute of Health Services and Policy Research and the Institute of

Neuroscience, Mental Health and Addiction, took early steps in bringing together 130 researchers, policy makers and international experts. Coordinated by Institute-affiliated researcher Dr. Grant McFadden, this meeting focused on strategies for containing biological threats and for fostering unique and effective Canadian research in this area.

Recommendations stemming from the conference included several strategies for optimizing Canada’s pre-emptive and containment capabilities. As attacks could affect the continent as a whole, joint initiatives, both at the research and political levels, must be developed with the U.S. and Mexico. New linkages among CIHR Institutes and among other Canadian government and defence entities must also be forged, with the aim of shaping a strategic approach to research and creating viable and potent response mechanisms. A precedent-setting step in this direction was taken with the Government of Canada’s creation of the Chemical, Biological, Radiological and Nuclear Research and Technology Initiative (CRTI). The fund, coordinated by the Department of National Defence, is a \$170 million resource with the explicit mandate of establishing these linkages among government, private industry and academic sectors.



Dr. Grant McFadden (Department of Microbiology and Immunology, the University of Western Ontario, and Roberts Research Institute) addresses the audience of a plenary session on viral agents at the CIHR/Health Canada-sponsored conference on bioterrorism.

**Table 4
Current Members of the Canadian Research Coalition for Food and Water Safety**

Agriculture and Agri-Food Canada	Canadian Water Network
Canadian Agri-Food Research Council	Chicken Farmers of Canada
Canadian Aquaculture Industry Alliance	Environment Canada
Canadian Bacterial Diseases Network	Genome Canada
Canadian Food Inspection Agency	Health Canada
Canadian Institutes of Health Research	National Research Council Canada
Canadian Pork Council	Natural Sciences and Engineering Research Council of Canada
Canadian Veterinary Medical Association	

Innovative Partnerships

The Research Agenda of Science and Technology Related to Food and Water Safety in Canada

Just days after the *E. coli* infections that led to seven deaths in Walkerton, Ont. in May 2000, a CIHR Opportunity Fund Workshop in Food Safety brought together 30 representatives from industry, academic and government sectors at the University of British Columbia to establish research and funding priorities in the areas of microbial food safety, food-borne and enteric infections. That meeting led the Institute two years later to champion the creation of a national coalition primed to stimulate research into microbiologically safe food and water. The current members are listed in Table 4.

To date, the parties have drafted a Memorandum of Understanding representing an agreement to collaborate and pool expertise with the aim of coordinating the national research process. Plans are underway for the launch of two rounds of strategic RFA in 2002.

Diabetes Stem Cell Consensus Conference

A decade ago, the term “stem cell” would have carried little significance for most individuals outside a select research community. Today, not a day passes when a new application for stem cell technology is not proposed, a new ethical dilemma broached, a new source of stem cells discovered, or new legislation introduced somewhere in the world.



The Stem Cell Network, one of 22 Networks of Centres of Excellence, was created to address the need for organized research into the biology of adult and embryonic stem cells, the ethical issues involved, and the potential therapeutic and commercial applications. The Institute signed a Memorandum of Understanding with the Stem Cell Network, the Juvenile Diabetes Research Foundation, CIHR and the Institute of Nutrition, Metabolism and Diabetes, to sponsor a research consensus conference March 21-22, 2002 addressing the application of stem cell technologies to the study and treatment of diabetes.

Better Health for the Poor: A Canadian Collaboration for Global Health

Diseases that are manageable in a first-world country are often debilitating or fatal for millions of children and women in developing countries. While steps have already been taken to mitigate these costs to health and quality of life, a holistic and far-sighted understanding of the health problems faced by developing countries, combined with the establishment of global health priorities, would contribute to better health outcomes and economic growth.

On behalf of all 13 Institutes, CIHR has signed a Memorandum of Understanding with the Canadian International Development Agency, Health Canada and the International Development Research Centre expressing a commitment to collaborate on international health research. Mechanisms of collaboration will include:

- Parallel funding of different components of joint research programs (e.g. complementary AIDS vaccine trials carried out both in Canada and in developing countries)
- Joint review of projects and programs through participation in relevant approval committees
- Co-funding of international health research projects and programs (e.g. global health systems research, and adapting promising findings with respect to HIV/AIDS interventions in Canada to developing country settings)





The Institute of Infection and Immunity has also participated in meetings with the Institutos Nacionale de Salud (INS) in Mexico. In January 2002, representatives from many CIHR Institutes met with the Health Secretariat of the United Mexican States. CIHR signed a Letter of Intent with the Health Secretariat, agreeing to work together on joint research initiatives in several areas, including environmental health, genetics and genomics, the needs of vulnerable populations, health services and policy, and communicable and non-communicable diseases.

The Institute of Infection and Immunity recognizes and pledges its support for global health issues, particularly those that fall within its mandate and within the expertise of its research community, including diseases such as hepatitis C and HIV/AIDS, food and water safety issues, a shortfall in research capacity in developing countries in the areas of infectious disease and immunity, and the global demand for vaccines offering protection against endemic diseases.



Translation and Use of Knowledge

The Institute of Infection and Immunity's early initiative in bringing together national and international experts to address the threat of bioterrorism attacks resulted in a series of recommendations for strengthening Canada's response. Conference participants identified unique strengths Canada already has that can be translated into active measures against bioterrorists, including the existence of research capacity and infrastructure in areas such as vaccine and bacterial research, in accelerated-response field detection and identification, in the existence of high-calibre animal and microbiological containment facilities; and of CIHR itself, with its mandate of supporting new research and collaborations. However, Canada requires further development of these areas and additional collaborative and strategic approaches to reach an ideal level of readiness.

The recommendations that emerged from the conference represented the combined expertise and diverse backgrounds of scientists, academics, policy makers, public health organizers, and military and industry representatives. These recommendations went forward through the national media covering the conference to inform the Canadian public. In their stories the media relayed Canadian strengths, weaknesses, needs and gaps in addressing bioterrorism threats.

For many Canadians, the media are the only source of information on research and policy issues relating to science and health. Institute-affiliated researchers are often called upon to provide expert commentary on significant issues, or to explain the results and applications of their own research. These commentaries assist members of the public in understanding exquisitely complex subjects. The knowledge and expertise of the Institute's affiliated researchers, in addition to flowing outward to the general public, also influence and inform the strategic directions undertaken by the Institute.

During the period of this report, Institute Advisory Board members and other Institute researchers have contributed their expertise to informing the public through the media on issues including:

- an *E. coli* vaccine that could prevent death and illness due to contaminated food and water
- vaccines preventing intrauterine transmission of viruses
- new vaccine delivery mechanisms for livestock
- Canada's containment capabilities for research on highly contagious pathogens
- biological weapons and agroterrorism





CIHR President Dr. Alan Bernstein in conversation with Dr. Luis Barreto, Vice President of Public Policy and Director of International Public Health Affairs at Aventis Pasteur Ltd., at the CIHR/Health Canada-sponsored conference on bioterrorism in January 2002.

- HIV/AIDS
- the dangers of cost-sharing public health plans for the poor and elderly
- a decrease in hospitalizations for asthma in children
- new asthma treatments for toddlers
- islet cell transplants for diabetics
- prenatal prevention of diabetes
- weapons against organ rejections in transplant patients
- xenotransplantation
- stem cells

CIHR, as Canada's primary health research agency, was responsible for translating the extensive and conflicting information about stem cells into guidelines within which its scientists could pursue their research. The Institute of Infection and Immunity has recognized both the tremendous healing potential of stem cell technologies and the ethical challenges associated with research in this area by identifying stem cell research as one of its strategic priority areas.



Organizational Excellence

Communication, Consultation and Engagement

CIHR is committed to a vision of creating a network of both national and international partners in health research, each bringing unique contributions to the table, thus enhancing the diversity and strength of strategies for the creation and translation of new health knowledge. The Institute of Infection and Immunity upholds this vision. While it is currently involved in fruitful partnerships with governmental, non-governmental, private sector and volunteer sector stakeholders, the Institute is actively seeking both additional partnerships and opportunities for knowledge exchange with these communities and the public.

In the past 15 months, the Institute's Scientific Director and staff members have participated in and presented at more than 70 national and international meetings, consultations, open forums, presentations and conferences. These events have allowed the Institute to solicit and pool information for devising research and funding strategies, communicate goals and achievements, establish partnerships, identify research priorities, and above all to begin the process of establishing the Institute of Infection and Immunity as a national and international contributor and leader in the health research community (see Appendix 2 for a complete list of Institute activities).

Highlights:

- Meetings, open forums and partnership discussions with six professional societies. February, October, April, June, August 2001, March 2002.
- Open forums and small group discussions at 12 universities across Canada. January, March, April, May 2001.
- Partnership meetings with the Kidney Foundation (Jan. 15, 2001), the Juvenile Diabetes Foundation International (with the Institute of Nutrition, Metabolism and Diabetes (INMD), Jan. 24, 2001), the Juvenile Diabetes Foundation Canada (with INMD, March 17, 2001), the Juvenile Diabetes Research Foundation Meeting and Discussion (May 17-19, 2001)
- Food and Water Safety Meetings. September 2001 – March 2002
- Bioterrorism: Canadian Research Agenda Conference. January 18-20, 2002.
- Ottawa Life Sciences Council: Superbugs, Infectious Diseases and Bioterrorism: The Community's Front Line – Presentation of the CIHR Initiative in Food, Water and Antibiotic Resistance. March 27, 2002
- HIV/AIDS Research Priorities Consultation in Montreal. Oct. 17, 2001
- Stem Cells and Diabetes Workshop with the Juvenile Diabetes Research Foundation and Stem Cell Network. March 21-22, 2002





- Partnership and informational meetings with officials at the Institutos Nacionales de Salud (Mexico). Jan. 28 – Feb. 1, 2002.
- CIDA/WHO/IDRC “Global Public Goods for Health, Experts’ Workshop: Making globalisation work to improve the health of the poor.” June 5, 2001

Leadership in National Health Research Issues

Safe Food and Water

In line with an Institute strategic priority area and with its mandate for the generation of partnerships, the Institute of Infection and Immunity has taken the initiative in the creation of a national, coordinated research strategy into issues of food and water safety as discussed above.

Spearheaded by Institute Liaison Officer Dr. Judith Bray, the process began with a letter to the Ministers of the relevant federal departments seeking an expression of interest

on a national research agenda. With the interest of several federal departments and a number of industry groups assured, 17 participants met on October 31, 2001, to review the scope and inventory of relevant ongoing research, and agreed in principle to define goals and mechanisms for the coordinated support of a national research agenda. Individual and small group follow-up meetings with participants subsequently led to the drafting of a Memorandum of Understanding for continued collaboration. An initial “Needs, Gaps and Opportunities Assessment” (NGOA) RFA is planned for May 2002. A larger scale RFA involving multiple federal departments will be launched in the fall of 2002.





Response to Bioterrorism

The Institute of Infection and Immunity's network of expertise and capacity for launching strategic initiatives equip it to take early responsibility for creating and supporting research programs and facilitating the linkage of scientific expertise in response to bioterrorism threats.

Just months after the anthrax scares that occurred in the wake of September 11, 2001 the Institute organized an international conference on bioterrorism with support from its partners Health Canada, the CIHR Institute of Population and Public Health, the Institute of Health Services and Policy Research, and the Institute of Neuroscience, Mental Health and Addiction. The conference was instrumental in starting a dialogue between disparate research communities, and recommendations stemming from the conference will contribute to the refinement and strengthening of Canada's bioterrorism response strategies.

Planning for the Future

Because of the "virtual" nature of the CIHR Institutes, each must be exceptionally attentive to establishing and maintaining communication links with its partners and the public. The Institute of Infection and Immunity has made a

commitment to strengthening its communications practices and will launch a quarterly newsletter. The newsletter will distribute information on funding opportunities and decisions, profile researchers, teams and projects, introduce Institute staff and Institute Advisory Board members, and offer commentary on issues relevant to the infection and immunity communities.

For daily communication requirements, the Institute relies on a combination of teleconferences, electronic mail, and the CIHR-based Institute website. For convening small meetings and gathering expert commentary on emerging issues, teleconferences have proven highly effective, and the capability for simultaneous interactive access to on-line documents (web-conferencing) will be available to the Institute next year. Email is already a mainstay for daily work, document exchange and surveys, and will be enhanced with a database of affiliated researchers and interested members of the public. To aid in the creation of this database, CIHR has launched an online sign-up feature for its mailing list that allows participants to select the Institutes from which they would like to receive updates.





The CIHR-based Institute of Infection and Immunity website continues to be refined and updated in response to the needs expressed by the research community. It provides information about the Institute's participation in national and international conferences, articles on Institute events, and information about both new and ongoing Requests for Applications.

CIHR and its 13 institutes have evolved quickly from fledgling organizations into powerful, effective and respected entities in the development and support of national health research. Throughout the process, the Institute of Infection and Immunity has sustained the flow of information between the Institute and

CIHR in Ottawa, the other 12 institutes and Institute of Infection and Immunity partners. In its first year, the Institute has established itself as an effective working model and a leader in infection and immunity research in Canada. With the development of its own strategic priorities as well as partnership involvements with CIHR and the other CIHR Institutes, the Institute of Infection and Immunity has mobilized stakeholders and brought together researchers and relevant communities to find solutions to existing and future challenges arising in the areas of infection and immunity.



Financial Statements

Funding sources

CIHR is funded entirely through federal government appropriations, which totaled \$553.8 million for the year ended March 31, 2002. CIHR Governing Council delegates financial authority to each institute for managing a portion of these funds that are described below:

- *Institute Strategic Initiatives:* Each institute is provided with funding annually to support strategic health research in their respective scientific areas by awarding peer-reviewed grants and awards.
- *Institute Support Grant:* Each institute receives a support grant of \$1 million annually to operate and to develop research capacity in the scientific community they represent through a wide array of collaborative activities.

The following tables provide financial results of operations for the year ended March 31, 2002 for each of these funding sources.

Institute of Infection and Immunity Investments in Strategic Initiatives

For the year ended March 31, 2002

Strategic Initiatives	Number	Contributions through Grants and Awards				Total
		2001-02	2002-03	2003-04	2004 and beyond	
Health Research Programs of Excellence (HRPE)	2	\$ 231,120	\$ 729,480	\$ 746,230	\$ 2,066,570	\$ 3,773,400
New Emerging Team Grant Program (NET Program)	3	13,315	158,625	158,625	462,561	793,126
Operating Grants	14	997,034				997,034
Strategic Training Initiative in Health Research	6	58,876	623,084	629,500	2,490,083	3,801,543
	25	\$ 303,311	\$ 2,508,223	\$ 1,534,355	\$ 5,019,214	\$ 9,365,103

Note: Grants and awards in respect to these programs are approved for 1 to 6 years. Figures displayed represent CIHR financial commitments for these programs in 2001-02 and subsequent years. Availability of these funds in future years is subject to funding appropriations by Parliament. For some initiatives, partners also contributed to the funding of the grants and awards.

**Institute of Infection and Immunity
Institute Support Grant**

For the year ended March 31, 2002

Available Funds		\$ 1,325,923
Expenses		
Institute Development		
Conference, symposia and workshops	\$ 53,595	
Institute Advisory Board	20,595	
Professional services	828	
Travel Expenditures	57,891	\$ 132,909
Institute Operations		
Salaries and benefits	\$ 249,722	
Office accommodations	9,999	
Telephone and communication services	1,988	
Supplies, material and other services	9,954	
Office furniture and fixtures	13,044	
Computer equipment and IT support	16,883	
Professional services	8,216	
Travel expenditures	39,888	\$ 349,694
Total Expenses		\$ 482,603
Unspent Balance*		\$ 843,320

* Note: The unspent balance as at March 31, 2002 is carried forward to the subsequent fiscal year.

Appendices

Appendix 1

Institute of Infection and Immunity Advisory Board

Researcher	Institution
Dr. Lorne A. Babiuk, Chair	Director, Veterinary Infectious Disease Organization Professor, Department of Veterinary Microbiology, University of Saskatchewan
Dr. Michel G. Bergeron, Vice-Chair	Professor and Director, Division of Microbiology and Infectious Diseases Research Center, Université Laval
Dr. Chris Bleackley	Professor, Department of Biochemistry, University of Alberta
Dr. Abdallah Daar	Director, Program in Applied Ethics and Biotechnology, Public Health Sciences and Surgery, University of Toronto
Dr. B. Brett Finlay	Professor, Biotechnology Laboratory, and the Departments of Biochemistry and Molecular Biology, and Microbiology and Immunology, University of British Columbia
Dr. Jack Gauldie	Professor and Chairman, Department of Pathology & Molecular Medicine, McMaster University
Dr. Kevin Glasgow	Chief Executive Officer, Cardiac Care Network of Ontario Assistant Clinical Professor, Department of Family Medicine, McMaster University Lecturer, Department of Public Health Sciences, University of Toronto
Dr. Philip Halloran	Director, Division of Nephrology and Immunology, University of Alberta
Dr. Noni MacDonald	Dean, Faculty of Medicine, Dalhousie University
Dr. Danielle Malo	Professeure agrégée, Scientifique, Centre universitaire de santé McGill, Hôpital général de Montréal
Dr. William E. Paul	Chief, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (NIAID Liaison to the Board)
Dr. Francis Plummer	Scientific Director, National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, Health Canada Professor, Department of Medical Microbiology, University of Manitoba
Ms. Helaine Shiff	Member, Research Partnership Program for the Juvenile Diabetes Research Foundation Partner, Focus on You Consultants
Dr. Steffanie Strathdee	Associate Professor, Infectious Diseases Program, Department of Epidemiology, Johns Hopkins School of Hygiene and Public Health
Dr. Robyn M. Tamblyn	Associate Professor, Department of Medicine & Dept. of Epidemiology & Biostatistics, McGill University

Appendix 2

Institute of Infection and Immunity Activities

Date	Event
December 4-6, 2000	Announcement of Institute Directors and First Scientific Directors Meeting, Ottawa, ON
December 19, 2000	Open Forum at Institut de recherches cliniques de Montréal, Montreal, QC
January 9, 2001	Reception at the University of Western Ontario President's House, London, ON
January 15, 2001	Partnership meeting with the Kidney Foundation, London, ON
January 16/17, 2001	Second Scientific Directors Meeting, Ottawa, ON
January 16/17, 2001	Health Canada Meeting on HIV/AIDS, Ottawa, ON
January 24, 2001	Joint partnership meeting with Juvenile Diabetes Foundation International (JDFI) and INMD, New York, NY
January 29, 2001	Open Forum and Small Group Discussions at Queen's University, Kingston, ON
February 22/23, 2001	Third Scientific Directors Meeting, Ottawa, ON
February 22/23, 2001	Joint Meeting with Scientific Directors and CIHR Governing Council, Ottawa, ON
February 22/23, 2001	Meeting with Health Canada – Prion Disease, Ottawa, ON
March 2, 2001	Open Forum at the University of Western Ontario, London, ON
March 15/16, 2001	First Institute Advisory Board Meeting, Ottawa, ON
March 17, 2001	Joint partnership meeting with Juvenile Diabetes Foundation Canada (JDFC) and INMD, Toronto, ON
March 18, 2001	Scientific Directors Scientific Retreat, Meech Lake, QC
March 19/20, 2001	Fourth Scientific Directors Meeting, Ottawa, ON
April 6-9, 2001	Canadian Society of Immunologists Annual Meeting Open Forum, Lake Louise, AB
April 6, 2001	Meeting with NCE-CANVAC, Lake Louise, AB
April 11/12, 2001	Fifth Scientific Directors Meeting, Ottawa, ON

Date	Event
April 19, 2001	Open Forum and Small Group Discussion at the University of Ottawa, Ottawa, ON
April 19, 2001	Open Forum and Small Group Discussion at Carleton University, Ottawa, ON
April 23, 2001	Open Forum and Small Group Discussions at the University of Manitoba, Winnipeg, MB
April 25, 2001	Institute Advisory Board, Teleconference
April 26, 2001	JDFC Annual Meeting Lecture and Open Forum, Toronto, ON
April 27, 2001	CIHR Announcement of Grants and Awards with Minister Rock, London, ON
April 28, 2001	Canadian Infectious Disease Society Annual Meeting Open Forum and Discussion, Huntsville, ON
April 30, 2001	Open Forum at Simon Fraser University, Vancouver, BC
May 1, 2001	Open Forum at University of British Columbia, Vancouver, BC
May 1, 2001	Small Group Discussion at Vancouver General Hospital, Vancouver, BC
May 2, 2001	Open Forum at University of Alberta, Edmonton, AB
May 3/4, 2001	First Canadian Conference on Hepatitis C, Montreal, QC
May 10, 2001	Open Forum at University of Calgary, Calgary, AB
May 11, 2001	Open Forum at University of Saskatchewan, Saskatoon, SK
May 17-19, 2001	Juvenile Diabetes Research Foundation Meeting and Discussion with INMD, New York, NY
May 23/24, 2001	Sixth Scientific Directors Meeting, Ottawa, ON
May 29, 2001	CIHR Accountability Workshop, Ottawa, ON
May 30, 2001	Partnership Meeting with Eli Lilly Canada, Toronto, ON
June 3, 2001	Open Forum with Canadian Association for AIDS Research, Toronto, ON
June 4, 2001	Second Institute Advisory Board Meeting, Toronto, ON

Date	Event
June 5, 2001	CIDA/WHO/IDRC "Global Public Goods for Health, Experts' Workshop – Making globalisation work to improve the health of the poor", Ottawa, ON
June 12, 2001	Open Forum at Canadian Society of Microbiology, Waterloo, ON
June 13, 2001	NCE-CANVAC Meeting, Montreal, QC
June 14/15, 2001	Seventh Scientific Directors Meeting, Ottawa, ON
June 27, 2001	Global Health Issues, Teleconference
June 28-July 1, 2001	Presentation and Discussion at Retreat for Dept. of Medical Microbiology & Infectious Diseases, the University of Manitoba, Gull Harbour, MB
July 4, 2001	III Visit to NIH, Teleconference
July 6, 2001	CIHR Review of institute liaison role, Teleconference
July 12, 2001	Presentation and Discussion at National Institute of Allergy and Infectious Disease at NIH regarding future joint initiatives, Washington, DC
July 19, 2001	Eighth Scientific Directors Meeting, Teleconference
July 22-27, 2001	International Congress of Immunology Presentation, Stockholm, Sweden
August 15, 2001	Communication Consultant Meeting, Cohn & Wolfe, Toronto, ON
August 16, 2001	Ninth Scientific Directors Meeting, Ottawa, ON
August 16, 2001	Meeting with Dr. Z. Chad, Canadian Society of Allergy and Clinical Immunology re: Partnership Potential Activities, Ottawa, ON
August 26, 2001	Proteomics Workshop (Institute of Genetics), Kingston, ON
August 30, 2001	Dr. B. Barber, Assistant VP Immunology, Aventis Pasteur, Teleconference
September 4, 2001	HIV/AIDS Strategic Initiatives, Teleconference
September 5, 2001	Food/Water Safety Partnership Workshop, Teleconference

Date	Event
September 9, 2001	Global Health Workshop (IPPH), Vancouver, BC
September 10, 2001	Joint Presentation to Ministerial Advisory Committee on HIV/AIDS with Dr. Alan Bernstein, Ottawa, ON
September 14/15, 2001	Tenth Scientific Director Meeting, Teleconference
September 26, 2001	Periodontal Disease Mini-symposium, London, ON
October 3, 2001	CIHR Peer Review Meeting with Panel Chairs and Scientific Officers, Ottawa, ON
October 4, 2001	Third Institute Advisory Board Meeting, Ottawa, ON
October 17, 2001	HIV/AIDS Research Consultation Co-sponsored by Institute of Infection and Immunity, Canadian HIV/AIDS Trial Network and Health Canada, Montreal, QC
October 18/19, 2001	Eleventh Scientific Directors Meeting, Ottawa, ON
October 26/27, 2001	Canadian Society of Allergy and Clinical Immunology/Canadian Allergy, Asthma, and Immunology Foundation Meeting, Banff, AB
October 31, 2001	Inaugural Food and Water Safety Research Coalition Meeting Organized by Institute of Infection and Immunity, Ottawa, ON
November 8/9, 2001	Twelfth Scientific Directors Meeting, Ottawa, ON
November 10, 2001	Canadian Federation of Biological Societies Strategic Planning Session, Ottawa, ON
November 21, 2001	Meeting with Health Canada re: HIV/AIDS Meeting with Mrs. S. Barnes, MP, Ottawa, ON
December 4/5, 2001	Thirteenth Scientific Directors Meeting, Ottawa, ON
December 6, 2001	CIHR, JDRF, StemNet Meeting, Ottawa, ON
December 12, 2001	Visit to Infectious Diseases Research Center and Presentation at Laval University, Sainte-Foy, QC
January 8, 2002	Canadian Strategy for HIV/AIDS – Direction Setting Planning Meeting, Ottawa, ON
January 8, 2002	CIHR Research Planning and Priorities Committee, Ottawa, ON
January 9, 2002	Fourteenth Scientific Directors Meeting, Ottawa, ON

Date	Event
January 10-13, 2002	Juvenile Diabetes Foundation Grant Review and Stem Cell Discussion, Miami, FL
January 18-20, 2002	Conference - "Biological Terrorism: Canadian Research Agenda" Sponsored by Infection and Immunity / Health Canada / Population and Public Health / Health Services and Policy Research / Neuroscience, Mental Health and Addiction, Toronto, ON
January 20/21, 2002	Fourth Institute Advisory Board Meeting, Toronto, ON
January 25, 2002	Interviews: CIHR Vice-President Research Selection, Ottawa, ON
January 28-February 1, 2002	Visit and Presentation to Institutos Nacionales de Salud (Mexico) with other CIHR Institutes, CIDA and Health Canada to discuss collaborative programs, Mexico City, Mexico
February 4, 2002	CIHR Research Planning and Priorities Committee, Ottawa, ON
February 5, 2002	Fifteenth Scientific Directors Meeting, Ottawa, ON
February 19, 2002	Environment and Health Steering Committee, Teleconference
February 23, 2002	National Immunization Strategy Consultation Meeting with Health Canada, Toronto, ON
March 1-3, 2002	Canadian Infectious Disease Society Meeting re: partnership, Banff, AB
March 2/3, 2002	Canadian Society for Transplantation Meeting – Presentation and potential partnership discussion, Mont Tremblant, QC
March 5, 2002	CIHR Research Planning and Priorities Committee, Vancouver, BC
March 6, 2002	Sixteenth Scientific Directors Meeting, Vancouver, BC
March 7, 2002	Standing Committee on the Oversight of Grants and Awards Competitions – Discussion re: strategic initiatives, Ottawa, ON
March 7, 2002	Meeting with Health Canada re: Food and Water Safety, Ottawa, ON
March 13, 2002	National Institutes of Health re: Biosecurity, Teleconference

Date	Event
March 14, 2002	Scientific Directors, Teleconference
March 21, 2002	Department of National Defence and CIHR, Teleconference
March 21/22, 2002	Stem Cells and Diabetes Workshop with Juvenile Diabetes Research Foundation and Stem Cell Network, Montreal, QC
March 26, 2002	Environmental Health Steering Committee, Ottawa, ON
March 27, 2002	Ottawa Life Sciences Council Meeting – Superbugs, Infectious Diseases & Bioterrorism: The Community's Front Line Meeting, Ottawa, ON
March 28, 2002	Meeting with Dr. N. Petersen, University of Western Ontario re: CIHR Institute Memorandum of Understanding, London, ON

Appendix 3

Acronyms	
CANVAC	The Canadian Network for Vaccines and Immunotherapeutics
CBDN	Canadian Bacterial Diseases Network
CIDA	Canadian International Development Agency
CIHR	Canadian Institutes of Health Research
CRTI	Chemical, Biological, Radiological and Nuclear Research and Technology Initiative
HIV/AIDS	Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
HRPE	Health Research Programs of Excellence
IA	Institute of Aging
IAB	Institute Advisory Board
IAPH	Institute of Aboriginal People's Health
ICR	Institute of Cancer Research
ICRH	Institute of Circulatory and Respiratory Health
IDRC	International Development Research Centre
IG	Institute of Genetics
IGH	Institute of Gender and Health
IHDCYH	Institute of Human Development, Child and Youth Health
IHSPR	Institute of Health Services and Policy Research
III	Institute of Infection and Immunity
IMHA	Institute of Musculoskeletal Health and Arthritis
INMD	Institute of Nutrition, Metabolism and Diabetes
INMHA	Institute of Neurosciences, Mental Health and Addiction
IPPH	Institute of Population and Public Health
JDFC	Juvenile Diabetes Foundation Canada
JDFI	Juvenile Diabetes Foundation International
JDRF	Juvenile Diabetes Research Foundation
NCE	Networks of Centres of Excellence
NET	New Emerging Teams
NGOA	Needs, Gaps and Opportunities Assessment
NIH	National Institutes of Health
RFA	Requests for application